Pharma manufacturers’ body raises industry concerns with Karnal MLA

The Haryana Pharmaceutical Manufacturers Association (HPMA) has raised key concerns of the pharmaceutical industry with Karnal MLA Jagmohan Anand, seeking policy support and regulatory relief to strengthen micro, small and medium enterprises (MSMEs) in the state. They raised these issues during a seminar on opportunities and growth of the pharma industry organised on Sunday.

They demanded extension of at least two years in the implementation of the revised Schedule-M for MSME units for smooth compliance, issuance of GMP and GLP certificates from zonal offices, on the lines of other tender-related certifications, to ease procedural delays, early establishment of the Karnal Pharma Park to promote investment and generate employment, provision of technical support and guidance to micro and small units for upgradation and regulatory compliance, and continuation of the hybrid mode (online and offline) system until the ONDLS portal becomes fully functional. Around 125 pharmaceutical manufacturers from various districts of Haryana attended the seminar.

HPMA president RL Sharma welcomed the guests and highlighted the concerns, while general secretary Vikas Parunti highlighted the association’s achievements over the past two years and outlined future goals, along with drawing attention to key challenges faced by the industry.

MLA Anand appreciated HPMA’s initiatives and assured full support. He said the demands would be taken up with the state government and that the request for an extension in the revised Schedule-M would be conveyed to the Centre through Union Minister Manohar Lal Khattar. He also assured that the demand for a Pharma Park in Karnal would be pursued seriously.

Lalit Goyal, State Drug Controller, briefed the association about the revised Schedule-M guidelines and emphasised the importance of maintaining quality standards.

Dr Ajay Sachan, Deputy Drug Controller, shared insights on export opportunities and regulatory coordination, while Ripan Mehta, Deputy State Drug Controller, stressed the need to strengthen cooperation between regulators and the industry.